Calling for stronger Indo-US collaboration in healthcare, Delhi’s Health Minister Dr Pankaj Kumar Singh invited US healthcare companies to bring their technologies to India at affordable prices, saying that such partnerships could help strengthen the country’s healthcare system and improve access to quality treatment.
“Indian doctors and the pharmaceutical industry have made a name for themselves across the world. I would urge the US representatives present here today and to the pharmaceutical companies to come to India with your technology at affordable prices. We welcome you, and together we can work towards strengthening the healthcare sector and providing affordable facilities to our people,” Dr Singh said while addressing the “23rd Indo-US Economic Summit” organised by the Indo-American Chamber of Commerce (IACC) in New Delhi on Thursday.
The India–U.S. healthcare partnership brings together India’s large-scale pharmaceutical manufacturing and public health workforce with U.S. biomedical research, regulatory systems, and health technology. It spans medicine supply chains, disease surveillance, and cancer research.
Addressing the session on Healthcare, Pharma & Life Sciences: Strengthening India-US Healthcare Partnerships: Innovation, Investment, Technology & Patient Access, the US Embassy’s Health Attaché and Regional Representative for South Asia, Genessa Giorgi, particularly highlighted strengthening of the pharmaceutical supply chain—a major priority for both US and India.
“India plays an integral role in the global pharmaceutical supply chain and is the world’s largest provider of generic medicines,” Giorgi said, with India supplying over 40 per cent of the generic medicines consumed in the United States. This partnership supports access to essential medicines for chronic conditions such as diabetes, heart disease and cancer, as well as antibiotics and cancer treatments.
Referring to the India-US Initiative on Critical and Emerging Technology (iCET), Ms Giorgi said the two countries were committed to strengthening their supply chains and enhancing their resilience to future challenges. Speaking about investment opportunities, Ms Giorgi highlighted the SelectUSA initiative and referred to $20.2 billion in investments announced by the US last May, of which $19.1 billion was in Indian pharmaceuticals and other sectors.
The session brought together a wide representation from the healthcare, pharmaceutical and medical technology sector to discuss opportunities for strengthening bilateral cooperation in innovation, investment, technology and patient access.
Henna Dhawan, Country Head, Public Affairs, Novartis India said that innovative medicines should be recognised for the breakthroughs they offer rather than viewed primarily in terms of their cost. “Healthcare is not a cost but an investment,” she observed.
Dr Bhuvnesh Shrivastava, Lead Corporate Affairs, OBU, AstraZeneca Pharma India Ltd, highlighted diversification as a key driver of growth in the pharmaceutical industry. He said companies needed to diversify their portfolios and invest in partnerships focused on innovation to sustain growth and respond to evolving healthcare needs.
The discussion also highlighted the need for regulatory frameworks to keep pace with technological advances in healthcare. Ashish Kothari, Partner, Kochhar & Co, called for greater integration of artificial intelligence and law, particularly as AI-based tools increasingly enter medical diagnosis. While technology was advancing rapidly, he pointed out that it also raised important questions of liability. “Technology is catching up, so law also needs to catch up,” he said.